Cardio Diagnostics Holdings, Inc.
CDIOHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Cardio Diagnostics Holdings, Inc. (CDIO) is listed under Biotechnology. The $5.0M market capitalization puts CDIO squarely in micro-cap range for its industry. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
Market Cap
$5.0M
Beta
2.24
P/E (TTM)
—
P/E (Fwd)
-6.76
EPS (TTM)
$-2.91
EPS (Fwd)
$-0.25
ROE
-75.4%
ROA
-44.1%
Cash
$5.6M
Total Debt
$369,698
Free CF
-$3.8M
52W Change
-56.8%
Annual Financials
Cash vs Debt
Where CDIO stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, CDIO finished 9.18% below its 150-day moving average ($1.96) and 16.82% below its 200-day moving average ($2.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CDIO overbought or oversold?
At the October 13, 2026 close, CDIO's RSI(14) was 38.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $5.6M in cash comfortably exceeding the $370K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$3.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -75.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $950 (2022) to $15K (2025), reflecting a 1461% increase over the period.
A beta of 2.24 means CDIO is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CDIO.